FAS PROPOSES MEASURES TO SUPPORT MEDICINES THAT COSTS UP TO 100 RUB

04-05-2020 | 12:35

A systemic approach proposed by the antimonopoly body will reduce the risk of vital and essential medicines in the low-end segment exiting the market. It will make them available for the population

 

The Federal Antimonopoly Service submitted its proposals to the Government of the Russian Federation to support medicinal medicines that cost less than 100 RUB and are on the list of vital and essential medicines.

 

Several Russian pharmaceutical manufacturers have already raised their voices that manufacturing medicines from the low-end segment is unprofitable.

 

“In fact, the unprofitability issue of manufacturing medicines from the low-end segment is long overdue and it is systemic. It relates directly to registering prices on the low economic base in 2010, changes in the Ruble exchange rate in 2014 and the system-wide non-application of the annual indexations to the inflation level by market players”, explains Head of FAS Department for Control over Social Sphere and Trade, Timophei Nizhegorodtsev. “Our main task now is to minimize the risk of medicine shortage”.

 

In this context, the antimonopoly authority finds it expedient to make amendments to the Rules for re-registering the maximum ex-works prices for vital and essential medicinal medicines in the part of clarifying the rules for re-registering prices on the medicines in the low-end segment. For example, FAS proposes to introduce mandatory re-registering of prices for generics on the basis of indicative parameters, as well as allow possible indexation for some generics.

 

At the same time, FAS believes that the current fluctuations of currency exchange rates should not affect the costs of vital and essential medicines so far. They will be supported, in particular, by the measures undertaken by the Government of the Russian Federation that have built up some safety margin.

 

Timophei Nizhegorodtsev argues that “considering reduction of customs rates from 2014 and annual indexation in the past two years, the safety margin just for foreign-made medicines in the current year has been 17.30 %. At the same time, the average euro to Ruble exchange rate in 2020 has increased by no more than 1.2% compared to the average price review rates in 2018, and reached 75.01 RUB”.



Site Map

News & Events Press Releases Media Releases Image Library About the FAS Russia What We Do General Information Mission, Goals, Values Priority Setting Institutional Memory Stakeholders Engagement Center for Education and Methodics Our History Our Structure Powers of Head and Deputy Heads Our Ratings GCR Using our website International Cooperation Treaties & Agreements International Working Groups Working Group on Research of Competition Issues in the Market of International Telecommunications (Roaming) Meetings Working Group for Studying Competition Problems in the Pharmaceutical Sector Concept Note Meetings OECD Competition Committee OECD meetings 2013 OECD meetings 2014 OECD meetings 2015 OECD meetings 2016 OECD meetings 2017 OECD meetings 2018 FAS Annual Reports OECD-GVH RCC RCC Newsletter ICAP Council on Advertising Headquarters for Joint Investigations UNCTAD 13th session IGE UNCTAD Resolution Russian contributions 14th session IGE UNCTAD Resolution Russian contributions 15th session IGE UNCTAD 16th session IGE UNCTAD 17th session IGE UNCTAD EEU Model Law on Competition ICN BRICS BRICS Conferences Documents BRICS Coordination Committee on antimonopoly policy BRICS Working Groups for the research of competition issues in socially important markets Cooperation within the BRICS BRICS Coordination Committee on antimonopoly policy EU APEC Competition Policy and Law Group Annual meetings Projects ERRA Full Members Organizational Structure Archive Working Group on Investigating Issues on Pricing in the Oil and Oil Product Markets and Methods of their Functioning Meetings Document Library Legislation Reports & Analytics Cases & decisions Contacts Give feedback Contact us Links Authorities Worldwide COVID-19